WO2009138734A3 - Use of opioid compounds in peripheral pain, wound healing and scar formation - Google Patents

Use of opioid compounds in peripheral pain, wound healing and scar formation Download PDF

Info

Publication number
WO2009138734A3
WO2009138734A3 PCT/GB2009/001184 GB2009001184W WO2009138734A3 WO 2009138734 A3 WO2009138734 A3 WO 2009138734A3 GB 2009001184 W GB2009001184 W GB 2009001184W WO 2009138734 A3 WO2009138734 A3 WO 2009138734A3
Authority
WO
WIPO (PCT)
Prior art keywords
wound healing
scar formation
peripheral pain
opioid compounds
opioid
Prior art date
Application number
PCT/GB2009/001184
Other languages
French (fr)
Other versions
WO2009138734A2 (en
Inventor
Andrew Douglas Baxter
Alan Rothaul
Original Assignee
Serentis Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0808753A external-priority patent/GB0808753D0/en
Priority claimed from GB0808754A external-priority patent/GB0808754D0/en
Priority claimed from GB0808755A external-priority patent/GB0808755D0/en
Application filed by Serentis Limited filed Critical Serentis Limited
Publication of WO2009138734A2 publication Critical patent/WO2009138734A2/en
Publication of WO2009138734A3 publication Critical patent/WO2009138734A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4

Abstract

A compound which is a quaternary ammonium salt derivative of an opioid, for use in therapy.
PCT/GB2009/001184 2008-05-14 2009-05-11 Use of opioid compounds in peripheral pain, wound healing and scar formation WO2009138734A2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB0808753A GB0808753D0 (en) 2008-05-14 2008-05-14 Use of opioid compounds in wound healing and scar formation
GB0808754.6 2008-05-14
GB0808754A GB0808754D0 (en) 2008-05-14 2008-05-14 Use of opiod compounds in peripheral pain
GB0808753.8 2008-05-14
GB0808755.3 2008-05-14
GB0808755A GB0808755D0 (en) 2008-05-14 2008-05-14 Use of opioid compounds in peripheral pain

Publications (2)

Publication Number Publication Date
WO2009138734A2 WO2009138734A2 (en) 2009-11-19
WO2009138734A3 true WO2009138734A3 (en) 2010-01-07

Family

ID=40825230

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2009/001184 WO2009138734A2 (en) 2008-05-14 2009-05-11 Use of opioid compounds in peripheral pain, wound healing and scar formation

Country Status (1)

Country Link
WO (1) WO2009138734A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012324012A1 (en) * 2011-12-08 2013-06-27 Purdue Pharma L.P. Quaternized buprenorphine analogs
CN105101964A (en) * 2013-01-21 2015-11-25 保罗·比利亚尔迪 Use of selective [delta]-opioid receptor antagonists and specific sensory receptor ligands
US20180318279A1 (en) * 2015-10-23 2018-11-08 Rush University Medical Center Topical compositions providing pain relief and methods of use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0897726A1 (en) * 1996-11-25 1999-02-24 Toray Industries, Inc. Antipruritic agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0897726A1 (en) * 1996-11-25 1999-02-24 Toray Industries, Inc. Antipruritic agent

Also Published As

Publication number Publication date
WO2009138734A2 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
WO2007075883A3 (en) Transdermal delivery of meptazinol
MX354509B (en) Combinations of akt inhibitor compounds and vemurafenib, and methods of use.
WO2010132999A8 (en) Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
NZ600379A (en) Morphinan derivatives for the treatment of drug overdose
WO2010014930A3 (en) Piperidine derivatives as jak3 inhibitors
WO2012045089A3 (en) Methods for the treatment of allergic diseases
AP2012006339A0 (en) Methods of administering pirfenidone therapy.
ZA201003350B (en) Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity
WO2011055944A3 (en) Methods for treating fibromyalgia syndrome
WO2012047645A3 (en) Combination treatment for rosacea
WO2012141796A3 (en) Prostate cancer therapy with hsp90 inhibitory compounds
EP1973601A4 (en) Iontophoretic transdermal delivery of nicotine salts
WO2012002687A3 (en) Methods for treating bipolar disorder
ME02066B (en) Crystalline forms of hydrochloride salt of (4a-r,9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2,3,4,4a,9,9a-hexahydro-1h-indeno [2,1-b]pyridine-6-carbonitrile and their use as hsd 1 inhibitors
WO2011083482A3 (en) Method for treatment of psoriasis
EP1883446B8 (en) An implantable therapy system for treating a living being with an active factor
WO2010025322A9 (en) Magnetic nanodelivery of therapeutic agents across the blood brain barrier
WO2009158646A8 (en) Therapeutic compounds and related methods of use
ZA201103576B (en) Hsp90 inhibitors for therapeutic treatment
IL213703A0 (en) Compounds and methods for the treatment of pain and other diseases
WO2009138734A3 (en) Use of opioid compounds in peripheral pain, wound healing and scar formation
IL225755A0 (en) 6-amido derivatives of 4,5a-epoxymorphinans for treatment of pain
NZ626112A (en) Triazinone compound and t-type calcium channel inhibitor
GB0622694D0 (en) Use of opioid compounds in wound healing
WO2012164055A3 (en) New compounds, synthesis and use thereof in the treatment of pain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09746051

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 31.05.11)

122 Ep: pct application non-entry in european phase

Ref document number: 09746051

Country of ref document: EP

Kind code of ref document: A2